First patient treated in study of neuromodulation device for Lennox-Gastaut Syndrome - Healio

NeuroPace Inc. announced that the archetypal diligent with Lennox-Gastaut Syndrome was treated successful its investigational instrumentality exemption feasibility study, which volition measure the company’s neuromodulation technology.

According to a merchandise from NeuroPace, the ongoing survey utilizes the RNS System, which has demonstrated information and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures successful adults, and volition measure whether brain-responsive neurostimulation tin besides beryllium utilized to dainty Lennox-Gastaut Syndrome (LGS).

NeuroPace Inc. announced the archetypal diligent was treated successful a feasibility survey of its brain-responsive stimulation strategy for attraction of Lennox-Gastaut syndrome. Source: Adobe Stock

The archetypal process took spot astatine Emory Healthcare successful Atlanta and was performed by Robert E. Gross, MD, PhD, the MBNA Bowman Chair successful Neurosurgery and prof and vice seat of the Emory University section of neurosurgery, the institution stated.

According to the release, NeuroPace received a $9.3 cardinal NIH assistance done the Brain Research done Advancing Innovative Neurotechnologies (BRAIN Initiative), which volition money valuation of the technology. The survey is expected to beryllium conducted astatine six sites and enroll 20 patients aged 12 years and older with LGS and drug-resistant generalized onset seizures.

“In summation to uncovering the champion detection and stimulation settings for responsive neurostimulation successful LGS, we are looking to place changes successful the recorded encephalon information that bespeak whether the therapy is effective,” Martha Morrell, MD, main aesculapian serviceman astatine NeuroPace, said successful the release. “These alleged biomarkers whitethorn assistance clinicians dainty LGS and besides facilitate aboriginal research, including the anticipation of a larger objective survey into the mechanisms of the illness and attraction approaches.”

At present, antiseizure medications are the standard-of-care attraction for LGS, the institution said, adding that seizures are seldom controlled — adjacent with aggregate medications — and it is emblematic for patients with LGS to acquisition expanding disablement implicit their lifetime.

“Overall, attraction is seldom effectual successful LGS, and the result remains precise poor,” Tracy Dixon-Salazar, PhD, enforcement manager of the LGS Foundation, said successful the release. “Those surviving with LGS request caller attraction options for the galore seizures, LGS-associated disorders and attraction side-effects our loved ones suffer.”